Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Literature DB >> 26629278

Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Loretta Fala.

Abstract

Entities: Disease Gene Species

Year: 2015 PMID： 26629278 PMCID： PMC4665063

Source DB: PubMed Journal: Am Health Drug Benefits ISSN： 1942-2962

× No keyword cloud information.

9 in total

1. Standards of medical care in diabetes--2013.

Authors:
Journal: Diabetes Care Date: 2013-01 Impact factor: 19.112

2. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Authors: Guillermo Umpierrez; Santiago Tofé Povedano; Federico Pérez Manghi; Linda Shurzinske; Valeria Pechtner
Journal: Diabetes Care Date: 2014-05-19 Impact factor: 19.112

3. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors: James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal: Popul Health Metr Date: 2010-10-22

4. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

Authors: Bernard M Y Cheung; Kwok Leung Ong; Stacey S Cherny; Pak-Chung Sham; Annette W K Tso; Karen S L Lam
Journal: Am J Med Date: 2009-05 Impact factor: 4.965

5. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson
Journal: Endocr Pract Date: 2013 May-Jun Impact factor: 3.443

Review 6. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.

Authors: Alan J Garber
Journal: Diabetes Care Date: 2011-05 Impact factor: 19.112

Review 7. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112

8. Economic costs of diabetes in the U.S. in 2012.

Authors:
Journal: Diabetes Care Date: 2013-03-06 Impact factor: 19.112

9. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Authors: Michael Nauck; Ruth S Weinstock; Guillermo E Umpierrez; Bruno Guerci; Zachary Skrivanek; Zvonko Milicevic
Journal: Diabetes Care Date: 2014-04-17 Impact factor: 19.112

9 in total

4 in total

Review 4. Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.

Authors: Elpiniki Rentzeperi; Stavroula Pegiou; Theocharis Koufakis; Maria Grammatiki; Kalliopi Kotsa
Journal: J Pers Med Date: 2022-03-13